Merit Medical Systems (NASDAQ:MMSI) Sets New 12-Month Low Following Analyst Downgrade

Merit Medical Systems, Inc. (NASDAQ:MMSI)’s stock price hit a new 52-week low during mid-day trading on Thursday after Wells Fargo & Company downgraded the stock from an overweight rating to an equal weight rating. Wells Fargo & Company now has a $78.00 price target on the stock, down from their previous price target of $95.00. Merit Medical Systems traded as low as $77.36 and last traded at $77.7480, with a volume of 295132 shares trading hands. The stock had previously closed at $79.23.

Several other equities analysts also recently issued reports on the stock. Zacks Research downgraded shares of Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Robert W. Baird set a $108.00 price target on shares of Merit Medical Systems in a research note on Tuesday, December 16th. Piper Sandler cut their price objective on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a research note on Wednesday, February 18th. Needham & Company LLC reduced their target price on Merit Medical Systems from $108.00 to $101.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Barrington Research lifted their price target on Merit Medical Systems from $106.00 to $109.00 and gave the stock an “outperform” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and an average price target of $103.33.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat expectations: EPS and revenue topped consensus, margins expanded driven by Cardiovascular strength and solid U.S. & EMEA sales — a fundamental driver supporting the stock. Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand
• Positive Sentiment: Barrington Research raised its price target to $109 and maintained an “outperform” rating, signaling bullish analyst conviction that the company can deliver upside from current levels. Barrington Research raises PT to $109
• Positive Sentiment: Management projects 6%–8% revenue growth for 2026 and is divesting the DualCap business to focus on strengthening global platforms—this strategic clarity and growth guide support medium‑term revenue expansion. Merit projects 6%-8% revenue growth for 2026 while divesting
• Neutral Sentiment: Earnings call presentation and detailed slides are available for review — useful for investors digging into segment performance and margin drivers but not new market-moving information on their own. Q4 results presentation
• Neutral Sentiment: Analyst notes and metric comparisons provide context on how the quarter stacks vs. estimates and prior-year numbers—helpful for modeling but not immediately directional. Zacks: Q4 key metrics vs estimates
• Neutral Sentiment: General earnings highlights and recap pieces summarize the beat and guidance for investors who want a quick read. Yahoo Finance earnings highlights
• Neutral Sentiment: Needham kept a Buy rating, citing the strong quarter and outlook, but trimmed its price target to $101 — a mixed signal (positive conviction on fundamentals, smaller near-term upside in the analyst view). TipRanks: Needham maintains Buy, lowers PT
• Negative Sentiment: Wells Fargo downgraded MMSI from Overweight to Equal Weight and cut its price target to $78, signaling reduced near-term conviction and adding selling pressure. Wells Fargo downgrades to Equal Weight

Institutional Trading of Merit Medical Systems

Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its holdings in shares of Merit Medical Systems by 2.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,973 shares of the medical instruments supplier’s stock worth $558,000 after buying an additional 131 shares during the last quarter. Norden Group LLC increased its stake in Merit Medical Systems by 5.7% during the third quarter. Norden Group LLC now owns 2,536 shares of the medical instruments supplier’s stock worth $211,000 after acquiring an additional 137 shares during the last quarter. Lido Advisors LLC raised its position in Merit Medical Systems by 3.8% in the fourth quarter. Lido Advisors LLC now owns 3,836 shares of the medical instruments supplier’s stock valued at $324,000 after purchasing an additional 140 shares during the period. Bryn Mawr Trust Advisors LLC raised its position in Merit Medical Systems by 7.2% in the second quarter. Bryn Mawr Trust Advisors LLC now owns 2,225 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 149 shares during the period. Finally, Hilltop National Bank grew its holdings in shares of Merit Medical Systems by 8.7% during the 3rd quarter. Hilltop National Bank now owns 2,119 shares of the medical instruments supplier’s stock worth $176,000 after purchasing an additional 169 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Trading Down 1.5%

The business has a fifty day moving average price of $83.73 and a two-hundred day moving average price of $84.89. The company has a current ratio of 4.34, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $4.64 billion, a PE ratio of 36.80, a PEG ratio of 2.15 and a beta of 0.61.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08. The company had revenue of $393.94 million for the quarter, compared to analysts’ expectations of $390.77 million. Merit Medical Systems had a net margin of 8.48% and a return on equity of 13.82%. Merit Medical Systems’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts expect that Merit Medical Systems, Inc. will post 3.37 EPS for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.